Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Press Release | 7 August 2025 at 11:30 EEST.
Herantis Pharma publishes its H1/2025 Report – invitation to a webinar
Espoo, Finland, 7 August 2025: Herantis Pharma, a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, will publish its H1/2025 Report on Thursday, 21st August 2025 at 8:00 EEST (7:00 CEST). The report will be available on the company website after publication.
Webcast on Thursday, 21st of August at 10:00 EEST (9:00 CEST)
Herantis CEO Antti Vuolanto and CFO Tone Kvåle will present the results of H1 and the status of the operations, followed by Q&A session. Questions can be submitted throughout the webcast event. Participants are invited to ask questions in English. The event and presentation will be held in English.
Shareholders, investors, analysts and media are invited to pre-register and join the online event using the following link: https://herantis.videosync.fi/q2-2025
The recording of the webcast will be available at the company’s website at https://herantis.com/news-events/public-materials/
For more information, please contact:
Herantis Pharma Plc
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
ICR Healthcare
Mary-Jane Elliott, Sarah Elton-Farr, Stephanie Cuthbert
Tel: +44 20 3709 5700
Email: herantispharma@icrhealthcare.com
Certified Advisor:
UB Corporate Finance Ltd
Tel: +358 9 25 380 225
Email: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. HER-096 is currently being evaluated in a Phase 1b clinical trial to assess the safety and tolerability of repeated subcutaneous dosing in patients with Parkinson’s disease. The study builds on positive Phase 1a results, where HER-096 demonstrated a favourable safety and tolerability profile, and effective brain penetration in healthy volunteers.
Herantis is listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com